Is Cronos a Buy After Reporting 51% Sales Growth in Q4?

Cronos Group (NASDAQ: CRON) hasn't been a really serious contender in the marijuana market. On the revenue front, it doesn't compare to the bigger vertically integrated cannabis businesses, and operationally, it struggles to turn a profit and continually burns through cash.

But it has been expanding its business and introducing new products, and based on the company's most recent quarterly results, those moves may be starting to pay off.

Image source: Getty Images.

Source Fool.com